Search
Vasomera
go.drugbank.com/drugs/DB16498InvestigationalCategories: Experimental Unapproved Treatments for COVID-19AMT-080
go.drugbank.com/drugs/DB17846ExperimentalAMT-080 is an investigational gene therapy being investigated for the treatment of Duchenne muscular dystrophy.
Tilarginine
go.drugbank.com/drugs/DB11815ApprovedInvestigationalWithdrawnTilarginine has been investigated for the basic science, treatment, and diagnostic of Obesity, Type 2 Diabetes, Ocular Physiology, and Regional Blood Flow.
Cannabinor
go.drugbank.com/drugs/DB05048ExperimentalCannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.
Methoxsalen
go.drugbank.com/drugs/DB00553ApprovedInvestigationalA naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation.
Categories: Antipsoriatics for Systemic Use, Antipsoriatics for Topical UseProducts: UVADEX 20 Mikrogramm/ml Lösung zur Modifikation einer Blutfraktion, Oxsoralen 20 Mikrogramm/ml-Lösung zur Modifikation einer BlutfraktionMethoxamine
go.drugbank.com/drugs/DB00723ApprovedInvestigationalWithdrawnAn alpha-adrenergic agonist that causes prolonged peripheral vasoconstriction. It has little if any direct effect on the central nervous system.
Categories: Adrenergic alpha-1 Receptor AgonistsEnoximone
go.drugbank.com/drugs/DB04880ApprovedInvestigationalWithdrawnEnoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with congestive heart failure. Trials were halted...
GTS-21
go.drugbank.com/drugs/DB05708InvestigationalGTS-21 (also known as DMBX-A), is a novel, small-molecule, orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor agonist that has demonstrated memory and cognition enhancement activity
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesBrodalumab
go.drugbank.com/drugs/DB11776ApprovedInvestigationalBrodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.
Categories: Interleukin-17 Receptor A Antagonist, Interleukin 17 Receptor A AntagonistsPhenoxybenzamine
go.drugbank.com/drugs/DB00925ApprovedInvestigationalAn alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.
Categories: Adrenergic alpha-1 Receptor Antagonists